Public Health Today—14 November, 2025

LucidQuest

4 days ago

This weekly roundup spans late-stage trial wins, real-world and epidemiologic signals, mechanistic breakthroughs, and policy/financing moves.We also cover early clinical proofs, device concepts, and lifestyle interventions shaping future care pathways.

In Today’s Newsletter

Dive deeper

💊 Pig kidney rejection mapped, biomarkers detect attacks early [1] [US • 13 Nov 2025]

https://abcnews.go.com/Health/scientists-discover-immune-reaction-pig-kidney-rejection-transplant/story?id=127446033
Context: NYU Langone study in a brain-dead patient with serial biopsies and fluids over two months, with companion Nature biomarker work.
Key point: Antibody and T-cell responses drove rejection; rejection was reversed with FDA-approved drugs, and blood biomarkers predicted attack up to five days early.
Implication: Clinical topline/efficacy, may influence prescriber choice and payer reviews pending full data.

🥗 Ultra-processed foods tied to higher early conventional adenoma risk in women under 50 [2] [13 Nov 2025]

https://www.theguardian.com/society/2025/nov/13/ultra-processed-foods-may-help-explain-rising-bowel-cancer-in-under-50s-study-suggests
Context: 29,105 participants in Nurses’ Health Study II, diet and colonoscopy data 1991–2015.
Key point: Highest UPF intake linked to 45 percent higher conventional adenoma risk; no association with serrated lesions.
Implication: Observational/RWE, could inform practice and payer discussions; interpretation depends on study design and confounding control.

🦠 Epstein–Barr virus reprograms immune system, strengthens causal link to lupus [3] [US • 12 Nov 2025]

https://med.stanford.edu/news/all-news/2025/11/lupus-epstein-barr.html
Context: Stanford mechanistic study of EBV-infected B cells.
Key point: EBV-infected B cells act as dominant regulators, altering other immune cells and promoting autoimmunity consistent with lupus biology.
Implication: Observational/RWE, could inform practice and payer discussions; interpretation depends on study design and confounding control.

🌍 WHO: Global tuberculosis diagnoses rose, deaths slight decline [4] [12 Nov 2025]

https://www.pbs.org/newshour/health/global-tuberculosis-case-rise-to-a-record-but-deaths-fall-reports-who
Context: WHO global TB update for 2024.
Key point: Diagnoses hit 8.3 million, deaths fell to 1.23 million, with rising US cases mainly among people born abroad and persistent funding gaps.
Implication: Clinical topline/efficacy, may influence prescriber choice and payer reviews pending full data.

🧪 Novartis’ KLU156 (GanLum) meets Phase III primary endpoint [5] [12 Nov 2025]

https://www.novartis.com/news/media-releases/novartis-phase-iii-trial-next-generation-malaria-treatment-klu156-ganlum-meets-primary-endpoint-potential-combat-antimalarial-resistance
Context: 1,668-patient Phase III across 12 African countries.
Key point: GanLum achieved high cure rates and outperformed standard therapy, including activity against partially resistant parasites with rapid gametocyte clearance.
Implication: Clinical topline/efficacy, may influence prescriber choice and payer reviews pending full data.

✂️ One-time CRISPR therapy CTX310 halves harmful lipids in Phase 1 [6] [08 Nov 2025]

https://www.nbcnews.com/health/health-news/harmful-cholesterol-levels-cut-half-one-time-gene-editing-drug-early-t-rcna242320
Context: 15-participant early-phase study in Australia, New Zealand, and the UK.
Key point: One infusion reduced LDL by 48.9 percent and triglycerides by 55.2 percent; short-term safety acceptable with limited events.
Implication: Clinical topline/efficacy, may influence prescriber choice and payer reviews pending full data.

☕ One cup of coffee daily reduced AFib recurrence by 39 percent (DECAF) [7] [12 Nov 2025]

https://www.medicalnewstoday.com/articles/1-cup-of-coffee-a-day-may-lower-afib-recurrence-risk-by-39
Context: Six-month randomized trial, 200 habitual coffee drinkers with persistent AFib.
Key point: Daily coffee lowered recurrence versus abstinence; multiple physiologic pathways proposed.
Implication: Observational/RWE, could inform practice and payer discussions; interpretation depends on study design and confounding control.

♨️ $300 million climate–health fund launched at COP30 [8] [14 Nov 2025]

https://www.reuters.com/sustainability/cop/deadly-heat-worldwide-prompts-300-mln-funds-climate-health-research-cop30-2025-11-13/
Context: Coalition of philanthropies and Brazil’s Belem Health Action Plan.
Key point: Funding targets extreme heat, pollution, and climate-driven infectious diseases, supplementing limited public investment.
Implication: Access programs, may expand screening, initiation, and follow-up at scale.

💉 TARGET-D: Tailored vitamin D dosing halved recurrent MI risk, preliminary results [9] [09 Nov 2025]

https://newsroom.heart.org/news/heart-attack-risk-halved-in-adults-with-heart-disease-taking-tailored-vitamin-d-doses
Context: 630 adults with prior MI, individualized targets of 40–80 ng/mL, 4.2-year median follow-up.
Key point: Recurrent MI risk fell by 52 percent versus standard care, with no significant effect on composite outcomes.
Implication: Clinical topline/efficacy, may influence prescriber choice and payer reviews pending full data.

🤖 Modular magnetic microrobots deliver drugs with high precision in animals [10] [13 Nov 2025]

https://www.news-medical.net/news/20251113/Modular-magnetic-microrobots-achieve-precision-drug-delivery.aspx
Context: Microrobot navigation and triggered release tested in vitro and in pigs and sheep.
Key point: System reached small, tortuous vessels and cerebrospinal regions, delivered drugs on demand, and then dissolved safely.
Implication: Partnerships/BD, signals pipeline investment and modality expansion.

Why it matters

Xenotransplantation insights and early biomarkers bring genetically modified pig organs closer to clinical feasibility, addressing transplant shortages.
Large cohort data strengthen links between ultra-processed foods and early precancerous lesions, informing prevention strategies in younger adults.
EBV mechanistic findings highlight viral contributions to autoimmune disease and potential therapeutic targets.
Rising TB detection paired with stagnant funding underscores global health system vulnerability.
Novel modalities, from CRISPR lipid editing to precision microrobotics, signal rapid expansion of therapeutic technology with far-reaching public health implications.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

View the full Public Health archive on our research hub page.

FAQ

How close are pig kidneys to clinical trials in living patients?

The NYU Langone study mapped immune drivers and demonstrated reversible rejection with existing drugs, but clinical use in living patients requires further safety data and regulatory review [1].

Do ultra-processed foods cause bowel cancer?

The NHS II analysis shows an association with higher adenoma risk in women under 50, but causation is unproven and relies on self-reported diet; findings inform dietary guidance rather than definitive causal claims [2].

Does the Stanford study prove EBV causes lupus?

It strengthens causal evidence by identifying immune reprogramming mechanisms, but further validation is needed before establishing EBV as a definitive cause of lupus [3].

Is GanLum ready for widespread malaria treatment?

GanLum met Phase III endpoints with strong cure rates, but regulatory approval and national program planning are needed before rollout [5].

Should people with heart disease take high-dose vitamin D?

A: TARGET-D suggests personalized dosing may reduce recurrent MI, but results are preliminary and require clinician supervision and replication before practice changes [9].

Entities / Keywords

NYU Langone, xenotransplantation, pig kidney; Nurses’ Health Study II, ultra-processed foods, early-onset adenomas; Epstein–Barr virus, lupus, Stanford; WHO, tuberculosis; Novartis, KLU156, GanLum; CTX310 CRISPR, ANGPTL3; DECAF, atrial fibrillation; COP30, climate–health fund; TARGET-D, vitamin D; microrobotics, image-guided drug delivery.